Association of myeloperoxidase with ovarian cancer

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 141-148

  Castillo Tong, Dan Cacsire ^a   Pils, Dietmar ^b   Heinze, Georg ^b   Braicu, Ioana ^c   Sehouli, Jalid ^c   Reinthaller, Alexander ^a   Schuster, Eva ^a   Wolf, Andrea ^a   Watrowski, Rafal ^a   Maki, Richard A ^d   Zeillinger, Robert ^a   Reynolds, Wanda F ^d  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d BURNHAM INSTITUTE   (United States)

Author keywords

FIGO; Lymph node; Myeloperoxidase; Ovarian cancer; Oxidative stress; Polymorphism

Indexed keywords

MYELOPEROXIDASE;

ADULT; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER TISSUE; COLLOID CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL;

ALLELES; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HUMANS; LYMPH NODES; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PEROXIDASE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 84893729694     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1017-3     Document Type: Article

References (53)

1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519-29.
2. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-8.
3. Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res. 2012;72:2701-4.
4. Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol: Off J U S Can Acad Pathol Inc. 2012;25:625-36.
5. Minegishi K, Tanaka M, Nishimura O, Tanigaki S, Miyakoshi K, Ishimoto H, et al. Reactive oxygen species mediate leukocyte-endothelium interactions in prostaglandin F2alpha-induced luteolysis in rats. Am J Physiol Endocrinol Metab. 2002;283:E1308-15.
6. Shirai F, Kawaguchi M, Yutsudo M, Dohi Y. Human peripheral blood polymorphonuclear leukocytes at the ovulatory period are in an activated state. Mol Cell Endocrinol. 2002;196:21-8.
7. Behrman HR, Kodaman PH, Preston SL, Gao S. Oxidative stress and the ovary. J Soc Gynecol Investig. 2001;8:S40-2.
8. Van Rensburg CE, Van Staden AM, Anderson R, Van Rensburg EJ. Hypochlorous acid potentiates hydrogen peroxide-mediated DNA-strand breaks in human mononuclear leucocytes. Mutat Res. 1992;265:255-61.
9. Gomez-Mejiba SE, Zhai Z, Gimenez MS, Ashby MT, Chilakapati J, Kitchin K, et al. Myeloperoxidase-induced genomic DNA-centered radicals. J Biol Chem. 2010;285:20062-71.
10. Klebanoff SJ, Kettle AJ, Rosen H, Winterbourn CC, Nauseef WM: Myeloperoxidase: a front-line defender against phagocytosed microorganisms. J Leukoc Biol. 2013;93:185-98.
11. Arnhold J, Flemmig J. Human myeloperoxidase in innate and acquired immunity. Arch Biochem Biophys. 2010;500:92-106.
12. Rossmann C, Rauh A, Hammer A, Windischhofer W, Zirkl S, Sattler W, et al. Hypochlorite-modified high-density lipoprotein promotes induction of HO-1 in endothelial cells via activation of p42/44 MAPK and zinc finger transcription factor Egr-1. Arch Biochem Biophys. 2011;509:16-25.
13. Maki RA, Tyurin VA, Lyon RC, Hamilton RL, DeKosky ST, Kagan VE, et al. Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of alzheimer disease. J Biol Chem. 2009;284:3158-69.
14. Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase. Curr Opin Hematol. 2000;7:53-8.
15. Castellani LW, Chang JJ, Wang X, Lusis AJ, Reynolds WF. Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463G males. J Lipid Res. 2006;47:1366-77.
16. Green PS, Mendez AJ, Jacob JS, Crowley JR, Growdon W, Hyman BT, et al. Neuronal expression of myeloperoxidase is increased in alzheimer's disease. J Neurochem. 2004;90:724-33.
17. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13:1176-84.
18. Malle E, Marsche G, Arnhold J, Davies MJ. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta. 2006;1761:392-415.
19. Reynolds WF, Hiltunen M, Pirskanen M, Mannermaa A, Helisalmi S, Lehtovirta M, et al. MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males. Neurology. 2000;55:1284-90.
20. Yuzhalin AE, Kutikhin AG. Common genetic variants in the myeloperoxidase and paraoxonase genes and the related cancer risk: a review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2012;30:287-322.
21. Saed GM, Ali-Fehmi R, Jiang ZL, Fletcher NM, Diamond MP, Abu-Soud HM, et al. Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer. Gynecol Oncol. 2010;116:276-81.
22. Olson SH, Carlson MD, Ostrer H, Harlap S, Stone A, Winters M, et al. Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol Oncol. 2004;93:615-20.
23. Fletcher NM, Jiang Z, Ali-Fehmi R, Levin NK, Belotte J, Tainsky MA, et al. Myeloperoxidase and free iron levels: potential biomarkers for early detection and prognosis of ovarian cancer. Cancer Biomark Sect A Dis Markers. 2011;10:267-75.
24. Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase - 463g->a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:181-4.
25. Pabalan N, Jarjanazi H, Sung L, Li H, Ozcelik H. Menopausal status modifies breast cancer risk associated with the myeloperoxidase (MPO) G463A polymorphism in Caucasian women: a meta-analysis. PLoS One. 2012;7:e32389.
26. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood. 1997;90:2730-7.
27. Ambrosone CB, Ahn J, Singh KK, Rezaishiraz H, Furberg H, Sweeney C, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res. 2005;65:1105-11.
28. Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, et al. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:4973-9.
29. Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant - 463A of the myeloperoxidase gene. Cancer Res. 2000;60:644-9.
30. Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, et al. Point: Myeloperoxidase -463G ->A polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1550-4.
31. Schabath MB, Spitz MR, Hong WK, Delclos GL, Reynolds WF, Gunn GB, et al. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer. 2002;37:35-40.
32. Vansant G, Reynolds WF. The consensus sequence of a major alu subfamily contains a functional retinoic acid response element. Proc Natl Acad Sci U S A. 1995;92:8229-33.
33. Reynolds WF, Kumar AP, Piedrafita FJ. The human myeloperoxidase gene is regulated by LXR and PPARalpha ligands. Biochem Biophys Res Commun. 2006;349:846-54.
34. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem. 1996;271:14412-20.
35. Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J Biol Chem. 2004;279:8300-15.
36. Van Schooten FJ, Boots AW, Knaapen AM, Godschalk RW, Maas LM, Borm PJ, et al. Myeloperoxidase (MPO) -463G-> A reduces mpo activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol Biomarkers Prev. 2004;13:828-33.
37. van der Veen BS, de Winther MP, Heeringa P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal. 2009;11:2899-937.
38. Song M, Santanam N. Increased myeloperoxidase and lipid peroxide-modified protein in gynecological malignancies. Antioxid Redox Signal. 2001;3:1139-46.
39. Reynolds WF, Stegeman CA. Tervaert JW: -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin Immunol. 2002;103:154-60.
40. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. Shih Ie M: Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218-24.
41. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, et al. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol. 1999;155:31-41.
42. Spencer JP, Whiteman M, Jenner A, Halliwell B. Nitrite-induced deamination and hypochlorite-induced oxidation of DNA in intact human respiratory tract epithelial cells. Free Radic Biol Med. 2000;28:1039-50.
43. Kensler TW, Egner PA, Moore KG, Taffe BG, Twerdok LE, Trush MA. Role of inflammatory cells in the metabolic activation of polycyclic aromatic hydrocarbons in mouse skin. Toxicol Appl Pharmacol. 1987;90:337-46.
44. Trush A, Esterline RL, Mallet WG, Mosebrook DR, Twerdok LE. Further evidence for the role of myeloperoxidase in the activation of benzo[a]pyrene-7,8-dihydrodiol by polymorphonuclear leukocytes. Adv Exp Med Biol. 1991;283:399-401.
45. Gungor N, Godschalk RW, Pachen DM, Van Schooten FJ, Knaapen AM. Activated neutrophils inhibit nucleotide excision repair in human pulmonary epithelial cells: role of myeloperoxidase. FASEB J Off Publ Fed Am Soc Exp Biol. 2007;21:2359-67.
46. Gungor N, Knaapen AM, Munnia A, Peluso M, Haenen GR, Chiu RK, et al. Genotoxic effects of neutrophils and hypochlorous acid. Mutagenesis. 2010;25:149-54.
47. Pero RW, Sheng Y, Olsson A, Bryngelsson C, Lund-Pero M. Hypochlorous acid/n-chloramines are naturally produced DNA repair inhibitors. Carcinogenesis. 1996;17:13-8.
48. Roncucci L, Mora E, Mariani F, Bursi S, Pezzi A, Rossi G, et al. Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:2291-7.
49. Rainis T, Maor I, Lanir A, Shnizer S, Lavy A. Enhanced oxidative stress and leucocyte activation in neoplastic tissues of the colon. Dig Dis Sci. 2007;52:526-30.
50. Park JH, Park JM, Kim EJ, Cha SI, Lee EB, Kim CH, et al. Myeloperoxidase -463G>A polymorphism and risk of primary lung cancer in a korean population. Cancer Detect Prev. 2006;30:257-61.
51. Schabath MB, Spitz MR, Zhang X, Delclos GL, Wu X. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis. 2000;21:1163-6.
52. Ahn J, Gammon MD, Santella RM, Gaudet MM, Britton JA, Teitelbaum SL, et al. Myeloperoxidase genotype, fruit and vegetable consumption, and breast cancer risk. Cancer Res. 2004;64:7634-9.
53. Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, et al. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis. 2004;25:973-8.